Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Non-Current Deffered Revenue data on record, last reported at $3.8 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 19.01% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, down 19.01%, while the annual FY2025 figure was $3.8 million, 19.01% down from the prior year.
  • Non-Current Deffered Revenue reached $3.8 million in Q4 2025 per CRNX's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $7.2 million in Q1 2022 and bottomed at $2000.0 in Q4 2021.
  • Average Non-Current Deffered Revenue over 5 years is $4.1 million, with a median of $4.7 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 91.3% in 2021, then soared 304950.0% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $2000.0 in 2021, then skyrocketed by 304950.0% to $6.1 million in 2022, then fell by 22.14% to $4.8 million in 2023, then decreased by 0.97% to $4.7 million in 2024, then fell by 19.01% to $3.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $3.8 million in Q4 2025, $4.1 million in Q3 2025, and $4.0 million in Q2 2025.